Healthcare > Pharmaceuticals & Biotechnology
•2438 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2438)
| Company | Market Cap | Price |
|---|---|---|
|
ESPR
Esperion Therapeutics, Inc.
Directly sells/markets cardiovascular drugs (NEXLETOL, NEXLIZET).
|
$796.41M |
$3.96
+7.18%
|
|
ALMS
Alumis Inc. Common Stock
Alumis is developing oral TYK2 inhibitors (ESK-001 and A-005), a major product category of oral small molecule therapeutics.
|
$795.05M |
$7.65
+4.37%
|
|
OCS
Oculis Holding AG
Direct ophthalmic drug products (OCS-01, OCS-02, OCS-05) are the core offerings: ophthalmic drugs.
|
$793.18M |
$18.92
-2.12%
|
|
REPL
Replimune Group, Inc.
Replimune is oncology-focused biotech developing oncolytic immunotherapies.
|
$785.24M |
$10.07
+5.67%
|
|
GHRS
GH Research PLC
GH Research's focus on neuropsychiatric drug development (CNS/psychiatric disorders) via 5-MeO-DMT therapies.
|
$767.42M |
$14.75
-0.97%
|
|
GOSS
Gossamer Bio, Inc.
Inhaled seralutinib represents a drug-delivery platform that concentrates therapy in the lungs to treat pulmonary hypertension, a major differentiator.
|
$759.45M |
$3.35
+2.45%
|
|
GERN
Geron Corporation
Geron directly develops and commercializes RYTELO (imetelstat), an oncology therapeutic indicated for lower-risk MDS.
|
$759.24M |
$1.20
+3.45%
|
|
GYRE
Gyre Therapeutics, Inc.
Gyre Therapeutics develops and commercializes small-molecule therapeutics (lead Hydronidone/F351 and multiple pipeline agents, plus licensed products) for fibrotic diseases, which fits the 'Oral Small Molecule Therapeutics' category.
|
$756.06M |
$7.86
+1.75%
|
|
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics is an oncology-focused biotech developing cancer therapies, anchoring its business in oncology.
|
$745.34M |
$5.38
+7.39%
|
|
EMBC
Embecta Corp.
Embecta provides contract manufacturing/partner manufacturing services and potential co-packaging arrangements.
|
$735.16M |
$12.62
-7.11%
|
|
CRMD
CorMedix Inc.
Melinta acquisition adds a diversified antibiotic portfolio expanding revenue mix into infectious disease therapeutics.
|
$720.36M |
$9.65
+2.66%
|
|
VTYX
Ventyx Biosciences, Inc.
VTX assets are oral small molecule therapeutics for autoimmune/inflammatory diseases (NLRP3 inhibitors).
|
$712.37M |
$10.00
-4.40%
|
|
ATXS
Astria Therapeutics, Inc.
Astria Therapeutics develops monoclonal antibody therapeutics (navenibart and STAR-0310).
|
$711.08M |
$12.62
+2.27%
|
|
KROS
Keros Therapeutics, Inc.
Duchenne muscular dystrophy (DMD) and associated cytopenias are rare diseases, aligning Keros Therapeutics' focused assets to Rare Diseases.
|
$710.77M |
$17.48
+0.95%
|
|
MYGN
Myriad Genetics, Inc.
Companion diagnostics—biomarker-based tests that stratify patients for targeted therapies; aligns with Myriad's genetic tests.
|
$707.14M |
$7.61
-3.79%
|
|
KALV
KalVista Pharmaceuticals, Inc.
EKTERLY (sebetralstat) is KalVista's lead asset and is an oral small-molecule therapeutic for acute hereditary angioedema, directly reflecting their product category.
|
$704.35M |
$14.11
+6.25%
|
|
KE
Kimball Electronics, Inc.
Strategic expansion into Contract Manufacturing Organizations for medical devices aligns with KE's Medical CMO focus.
|
$698.95M |
$28.90
+1.16%
|
|
CTMX
CytomX Therapeutics, Inc.
CX-2051 is a lead antibody-drug conjugate (ADC) using the PROBODY platform, making Antibody-Drug Conjugates the direct product category.
|
$695.93M |
$4.21
+1.57%
|
|
CGEM
Cullinan Therapeutics, Inc.
Cullinan develops bispecific antibodies (CD19xCD3 and BCMAxCD3) as core assets.
|
$693.53M |
$11.74
-0.42%
|
|
ORGO
Organogenesis Holdings Inc.
ReNu knee osteoarthritis program is a cell therapy (biotech) product, aligning with Biotech - Cell Therapy.
|
$687.57M |
$5.43
+2.84%
|
|
CRVS
Corvus Pharmaceuticals, Inc.
Lead pipeline includes oncology-focused therapies (soquelitinib) with activity in T-cell lymphomas, aligning with Oncology-focused biotech development.
|
$675.84M |
$9.06
+2.20%
|
|
RGNX
REGENXBIO Inc.
Core product category: gene therapy using NAV AAV platform.
|
$669.82M |
$13.26
-1.45%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$662.61M |
$9.45
+8.12%
|
|
MGTX
MeiraGTx Holdings plc
Core business involves developing gene therapies using AAV vectors and a riboswitch platform; MeiraGTx is a clinical-stage biotechnology company focused on genetic medicines.
|
$659.67M |
$8.21
+8.25%
|
|
OMER
Omeros Corporation
Narsoplimab and zaltenibart OMS906 are monoclonal antibody therapeutics, a core product class for Omeros.
|
$655.38M |
$9.63
+1.90%
|
|
VSTM
Verastem, Inc.
Company is a oncology-focused biotech developing and commercializing cancer therapeutics.
|
$654.23M |
$10.63
+3.76%
|
|
IRWD
Ironwood Pharmaceuticals, Inc.
LINZESS is a peptide-based therapeutic, aligning with the Peptide Therapeutics investable theme.
|
$627.00M |
$3.87
+23.48%
|
|
PROK
ProKidney Corp.
Core product is rilparencel (REACT), an autologous cell therapy for preserving kidney function in CKD, fitting the Biotech - Cell Therapy category.
|
$623.88M |
$2.12
+1.19%
|
|
AQST
Aquestive Therapeutics, Inc.
Aquestive's PharmFilm drug-delivery platform enables non-invasive, thin-film administration of complex molecules; Anaphylm and Libervant employ this platform.
|
$620.28M |
$6.21
+1.97%
|
|
SRDX
Surmodics, Inc.
The company provides proprietary drug-delivery platform technologies used on medical devices (SurVeil DCB) and related platforms.
|
$614.58M |
$42.98
|
|
FULC
Fulcrum Therapeutics, Inc.
Fulcrum's lead asset pociredir is an oral small molecule therapeutic intended to induce HbF in SCD.
|
$612.32M |
$11.32
-1.91%
|
|
HYEX
Healthy Extracts Inc.
Exclusive rights to an oral delivery technology for nutritional supplements, a distinctive platform that differentiates the company’s product delivery.
|
$610.02M |
$2.25
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$589.53M |
$11.05
+0.96%
|
|
PRTA
Prothena Corporation plc
Prothena's core assets are monoclonal antibody therapeutics (PRX012, PRX019, PRX123, etc.) across neurodegenerative diseases, including Alzheimer's and other indications.
|
$561.45M |
$10.43
-0.67%
|
|
RAPT
RAPT Therapeutics, Inc.
RAPT's pipeline includes oncology-focused assets under Biotech - Oncology (tivumecirnon) and broader oncology immunotherapy focus.
|
$550.05M |
$33.26
+10.98%
|
Showing page 10 of 25 (2438 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
